ClinicalTrials.gg
Not yet recruitingNCT07373613Updated Jan 28, 2026

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

A Phase 2 interventional study of BR1400-1 and BR1400-2 in Essential Hypertension, sponsored by Boryung Pharmaceutical Co., Ltd. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd — 8 open to participants now, 8 under way, 1 of them phase 3. Essential Hypertension · Boryung Pharmaceutical Co., Ltd.

Planned enrollment
2nd of 39
330 · median 58
Started
2026
with 5 others
Phase 2
4 of 44
1 open now
Registered
39th of 44
by date

Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, this one is the 2nd largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2026, is one of 4 in phase 2, and was the 39th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

8 of the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, or all of them as a file.
02

Study summary

The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

\<Screening Visit (V1)>

Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:

  • For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP \< 180 mmHg
  • For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP \< 180 mmHg

For patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study.

\<Baseline Visit (V2)>

Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:

  • For patients without cardiovascular disease: 140 mmHg ≤ MSSBP \< 180 mmHg
  • For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP \< 180 mmHg

Exclusion criteria

Exclusion Criteria:

  • Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2)
  • Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
  • Patients with shock
  • Patients with orthostatic hypotension accompanied by symptoms
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    BR1400-1 + BR1400-B + BR1400-C

    Patients will receive tablet BR1400-1 + BR1400-B (Placebo of BR1400-2 \& BR1400-4)+ BR1400-C (Placebo of BR1400-5)

    Drug: BR1400-1 · Drug: BR1400-B · Drug: BR1400-C

  • Experimental
    BR1400-A + BR1400-2 + BR1400-C

    Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-2 + BR1400-C (Placebo of BR1400-5)

    Drug: BR1400-2 · Drug: BR1400-A · Drug: BR1400-C

  • Experimental
    BR1400-3 + BR1400-B + BR1400-C

    Patients will receive BR1400-3 + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-C (Placebo of BR1400-5)

    Drug: BR1400-3 · Drug: BR1400-B · Drug: BR1400-C

  • Experimental
    BR1400-A + BR1400-4 + BR1400-C

    Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-4 + BR1400-C (Placebo of BR1400-5)

    Drug: BR1400-4 · Drug: BR1400-A · Drug: BR1400-C

  • Other
    BR1400-A + BR1400-B + BR1400-5

    Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-5

    Drug: BR1400-5 · Drug: BR1400-A · Drug: BR1400-B

  • Placebo comparator
    BR1400-A + BR1400-B + BR1400-C

    Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-C (Placebo of BR1400-5)

    Drug: BR1400-A · Drug: BR1400-B · Drug: BR1400-C

Interventions

  • DrugBR1400-1

    One tablet administered alone

  • DrugBR1400-2

    One tablet administered alone

  • DrugBR1400-3

    One tablet administered alone

  • DrugBR1400-4

    One tablet administered alone

  • DrugBR1400-5

    One tablet administered alone

  • DrugBR1400-A

    One tablet administered alone

    Also known as: Placebo

  • DrugBR1400-B

    One tablet administered alone

    Also known as: Placebo

  • DrugBR1400-C

    One tablet administered alone

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline to treatment of 8 weeks in MSSBP

    Time frame: 8 weeks

07

Study locations

1 site
  • Hanyang University Hospital
    Soeul, South Korea
    • Jinho Shin, MD.,PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Feb 2027, 11 months later.

Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 28, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07373613
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Soo Hee Kim
Contact
shkim0127@boryung.co.kr
+82-2-708-8000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion